|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's Range||192.73 - 197.11|
|52 Week Range||163.31 - 201.23|
|PE Ratio (TTM)||58.85|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||5.28 (2.69%)|
|1y Target Est||204.26|
In the August Action Alerts PLUS members' call, Jim Cramer and Jeff Marks, Senior Portfolio Analyst of Action Alerts PLUS, discuss the portfolio's new edition of Amgen.
Nektar Therapeutics (NKTR) generated revenue of $1.09 billion in the second quarter compared to $34.59 million in the second quarter of 2017.
GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.
Stocks entered the weekend on a sour note. Turkey currency woes were all the excuse needed to end the multi-day rally that had carried the S&P 500 within a whisker of all-time highs. But one day does not a downtrend make. My weekend scanning revealed many “strong buys” that deserve a top spots on your list of stocks to buy.
Attention dividend hunters! Amgen Inc (NASDAQ:AMGN) will be distributing its dividend of US$1.32 per share on the 07 September 2018, and will start trading ex-dividend in 2 days time onRead More...
Alnylam Pharmaceuticals’ (ALNY) investigational RNAi therapeutic drug lumasiran is being developed for the treatment of primary hyperoxaluria type 1 (or PH1). Alnylam expects to initiate a Phase 3 trial of the drug in 2018, with its results expected in late 2019.
Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.
BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.
Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.
Mylan stock tumbled after the drugmaker missed second-quarter expectations, issued lagging guidance for 2018 and announced a strategic review.
A change is coming to the stock market in which investors are beginning to favor value stocks over growth ones as the economy enters the late stages of its growth cycle. According to a report in CNBC, citing Gina Sanchez, CEO of Chantico Global, signs are emerging that investors are looking at value stocks, which tend to be more of a defensive bet over their high-flying brethren in the growth camp. Growth stocks, namely tech ones, have been fueling the nine-year bull run in stocks, but with rising trade tensions and a widely held belief that earnings growth has or will soon peak, investors are setting their sights elsewhere.
Thanks to the Republican tax plan and increasing revenues, investors are seeing a bit more green in their pockets. Momentum in iPhone sales, as well as record services revenues, helped the consumer tech giant realize a big jump in operating cash flows.
Pfizer (PFE) reported a rise in revenue in international markets during the second quarter. The Innovative Health segment reported a rise of 3% in revenue to ~$4.58 billion, while the Essential Health segment reported a ~14% fall in revenue to $1.65 billion. The rise in the Innovative Health segment was driven by a 5% rise in vaccines sales, a 5% rise in oncology sales, a 33% rise in inflammation and immunology sales, and a 1% rise in consumer healthcare sales.
BeiGene (BGNE) reported revenues of $32.5 million and EPS of -$2.03 in the first quarter. Analysts expect BeiGene to report EPS of -$2.06 on revenues of $22.5 million during the second quarter. This represents 100.0% growth in its YoY (year-over-year) revenues, compared to zero revenues during the second quarter of 2017. The chart below compares analysts’ recommendations over the last 12 months.
A bull market powered by rocket fuel has sent growth stocks like Amazon AMZN and Netflix NFLX sky high for close to a decade. Now some market watchers are anticipating a change in the air. There are signs investors are beginning to favor value stocks, typically a defensive play, over riskier growth stocks, according to Gina Sanchez , CEO of Chantico Global.
Yesterday, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new vial presentation and indication in pediatric patients aged one month or older. Granix is a short-acting G-CSF (granulocyte colony-stimulating factor) that was approved by the FDA in 2012 for use in adults.
Utilities, consumer staples and healthcare stocks all suffered under the onslaught of higher interest rates. Of the trio, Healthcare is the closest to reclaiming its prior peak. In fact, at $90, the Healthcare Sector SPDR Fund (NYSEARCA:XLV) is less than 2% away from record highs.
Mylan (MYL) plans to release its second-quarter earnings results on August 8. In this part of the series, we’ll look at Wall Street analysts’ recent recommendations and 12-month target prices for Mylan.
What Do Analysts Expect from Ionis’s Second-Quarter Earnings? Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017. Ionis’s stock price has decreased by nearly 14.5% over the last 12 months and decreased by ~14.3% in 2018 year-to-date.